Side effects associated with prostaglandin analog therapy.
Authors: Alm A, Grierson I, Shields MB Topical prostaglandin analogs, which have become first-line therapy in the medical management of glaucoma, have an excellent safety profile with regard to systemic side effects, but are associated with several ocular side effects. Some of these are common, with no apparent serious consequences other than cosmetic, whereas others are much less common but represent potentially sight-threatening side effects. The former group includes conjunctival hyperemia, elongation and darkening of eyelashes, induced iris darkening, and periocular skin pigmentation.
More:
Side effects associated with prostaglandin analog therapy.
Estimating Corneal Surface Topography in Videokeratoscopy in the Presence of Strong Signal Interference
Videokeratoscopy techniques rely on a number of factors in order to achieve accurate estimates of corneal surface topography. Good tear film quality, minimal reflections from eyelashes, and minimal eye movements are essential for corneal topography estimates to be reliable
Here is the original post:
Estimating Corneal Surface Topography in Videokeratoscopy in the Presence of Strong Signal Interference
Prostaglandin analogues in the anterior eye: Their pressure lowering action and side effects.
We report here the findings from many studies which strongly indicate that there are no histopathological changes occurring in the iris tissue that has developed the darkening side effect. The only definitive change that has been detected in the cases of PIID is a small enlargement of the size of the existing melanin granule population and it has been shown that this change in melanin granule size is sufficient to account for the PIID. These findings point to the conclusion that the darkening developed following PG use is of a purely cosmetic effect with little or no serious consequences
See the original post:
Prostaglandin analogues in the anterior eye: Their pressure lowering action and side effects.